Full-Time
Associate Director
Product Characterization, In Vivo CAR-T
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
No salary listed
Malvern, PA, USA
In Person
PhD
 Biology & Biotech (1) |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- A Ph.D. in Immunology, Biochemistry, Virology, Molecular Biology, Bioengineering, Analytical Chemistry, Pharmaceutical Sciences, or a related field.
- A minimum of 6–8+ years of relevant industry experience in analytical development for advanced therapy modalities, including demonstrated scientific leadership, cross-functional influence, and strategy ownership in cell and gene therapy development.
- Deep scientific expertise in immunology and lentivector mechanisms, with strong understanding of immune cell biology, in vivo gene delivery, vector targeting, transduction, CAR expression, and functional T cell biology as applied to in vivo CAR-T therapeutic development.
- In-depth knowledge of regulatory requirements and industry best practices related to analytical comparability and product characterization.
- Strong leadership, communication, and interpersonal skills with a proven ability to influence stakeholders and drive collaborative efforts.
- Lead and manage a team of scientists focused on analytical comparability and product characterization for in vivo and ex vivo cell therapy, ensuring robust strategy development in alignment with statistical rigor and global health authority expectations.
- Oversee the ideation, development, and implementation of advanced analytical methodologies associated with comparability and deep characterization of cell and gene therapy products.
- Set the overarching scientific and technical strategy for in vivo CAR-T lentivector characterization, shaping cross-functional product understanding and control strategy to support portfolio decisions, regulatory readiness, and advancement of next-generation cell and gene therapy platforms.
- Lead development of phase-appropriate critical quality attribute and control strategy frameworks for targeted lentiviral vectors, linking process parameters, product quality attributes, mechanism of action, transduction efficiency, biodistribution, insertional risk, and functional CAR-T cell generation to support development decisions.
- Apply deep immunology and lentivector mechanism expertise to guide product characterization strategy, including understanding of immune cell targeting, in vivo transduction biology, vector-mediated CAR expression, and functional generation of therapeutic CAR-T cells.
- Drive strategic scientific communication for internal governance, senior leadership, external partners, and regulatory interactions, ensuring complex technical data are translated into clear recommendations and development decisions.
- Collaborate cross-functionally with Process Development, Translational, Discovery, Quality Assurance, Regulatory Affairs, and manufacturing teams to integrate analytical strategies within broader development processes.
- Analytical reasoning.
- Biochemistry.
- Chemistry, Manufacturing, and Controls (CMC).
- Clinical research and regulations.
- Clinical trial designs.
- Developing others.
- Drug discovery and development.
- Inclusive leadership.
- Leadership.
- Molecular diagnostics.
- Pharmacovigilance.
- Process improvements.
- Productivity planning.
- Program management.
- Quality assurance.
- Scientific research.
- Tactical planning.
- Team management.
- Troubleshooting.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
- TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
- The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.
What critics are saying
- Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
- The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
- A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.
What makes Johnson & Johnson unique
- J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
- TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
- TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.
Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.
Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.
Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.
Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.